CIBMTR Reporting Implementation Guide
0.1.8 - Trial Use 1
CIBMTR Reporting Implementation Guide
0.1.8 - Trial Use 1
This page is part of the CIBMTR Reporting Implementation Guide (v0.1.8: Release Draft) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version. For a full list of available versions, see the Directory of published versions
Generated Narrative: MedicationRequest MedicationRequest-Etoposide-Example
status: Active
intent: Order
medication: etoposide (VEPESID) chemo IVPB
subject: Female, DoB Unknown ( http://terminology.cibmtr.org/identifier/CRID#123456)
authoredOn: 2020-07-21 14:17:00+0000
requester: unknown
reasonCode: Cancer (CMS/HCC)
dosageInstruction
text: 68 mg (100 mg/m2 x 0.68 m2 Treatment plan actual BSA), Intravenous, for 60 Minutes, Every 24 hours, First dose on Tue 11/19/13 at 0000, For 5 doses Give after CISplatin and mannitol.
timing: Code , Count 5 times, Duration 60hours , Once per 24 hours
asNeeded: false
route: Intravenous central route (qualifier value)
doseAndRate
type: admin-amount
dose: 68 milligram (Details: UCUM codemg = 'mg')
doseAndRate
type: ordered
dose: 100 milligram per square meter (Details: UCUM codemg/m2 = 'mg/m2')